LT2556150T - Išlaisvinama po žinduolio ląstelių užkrėtimo žmogaus citomegalovirusu (hcmv) virusinė dalelė, turinti sulietą baltymą, ir jos panaudojimas - Google Patents

Išlaisvinama po žinduolio ląstelių užkrėtimo žmogaus citomegalovirusu (hcmv) virusinė dalelė, turinti sulietą baltymą, ir jos panaudojimas

Info

Publication number
LT2556150T
LT2556150T LTEP11713689.5T LT11713689T LT2556150T LT 2556150 T LT2556150 T LT 2556150T LT 11713689 T LT11713689 T LT 11713689T LT 2556150 T LT2556150 T LT 2556150T
Authority
LT
Lithuania
Prior art keywords
hcmv
infection
fusion protein
mammalian cells
viral particle
Prior art date
Application number
LTEP11713689.5T
Other languages
English (en)
Inventor
Sabine Becke
Sabine Reyda
Bodo Plachter
Original Assignee
Vakzine Projekt Management Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vakzine Projekt Management Gmbh filed Critical Vakzine Projekt Management Gmbh
Publication of LT2556150T publication Critical patent/LT2556150T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16161Methods of inactivation or attenuation
    • C12N2710/16162Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP11713689.5T 2010-04-06 2011-04-06 Išlaisvinama po žinduolio ląstelių užkrėtimo žmogaus citomegalovirusu (hcmv) virusinė dalelė, turinti sulietą baltymą, ir jos panaudojimas LT2556150T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10003712 2010-04-06
PCT/EP2011/001712 WO2011124371A1 (en) 2010-04-06 2011-04-06 Viral particle released after infection of mammalian cells by human cytomegalovirus (hcmv) containing a fusion protein and use thereof

Publications (1)

Publication Number Publication Date
LT2556150T true LT2556150T (lt) 2016-12-12

Family

ID=43923731

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP11713689.5T LT2556150T (lt) 2010-04-06 2011-04-06 Išlaisvinama po žinduolio ląstelių užkrėtimo žmogaus citomegalovirusu (hcmv) virusinė dalelė, turinti sulietą baltymą, ir jos panaudojimas

Country Status (25)

Country Link
US (1) US9486517B2 (lt)
EP (1) EP2556150B1 (lt)
JP (1) JP5827312B2 (lt)
KR (2) KR20170108167A (lt)
CN (1) CN102933706B (lt)
AU (1) AU2011238085B2 (lt)
BR (1) BR112012025392B1 (lt)
CA (1) CA2795346C (lt)
CY (1) CY1118138T1 (lt)
DK (1) DK2556150T3 (lt)
ES (1) ES2601850T3 (lt)
HR (1) HRP20161556T1 (lt)
HU (1) HUE030704T2 (lt)
IL (1) IL222229A (lt)
LT (1) LT2556150T (lt)
MX (1) MX2012011639A (lt)
MY (1) MY162335A (lt)
PL (1) PL2556150T3 (lt)
PT (1) PT2556150T (lt)
RS (1) RS55421B1 (lt)
RU (1) RU2623172C2 (lt)
SG (2) SG10201502271RA (lt)
SI (1) SI2556150T1 (lt)
SM (1) SMT201700002B (lt)
WO (1) WO2011124371A1 (lt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011101446A1 (de) * 2011-05-10 2012-11-15 Aicuris Gmbh & Co. Kg Herstellung von "Dense Bodies" (DB)
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
MA46316A (fr) 2015-10-22 2021-03-24 Modernatx Inc Vaccin contre le cytomégalovirus humain
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
CA3041307A1 (en) 2016-10-21 2018-04-26 Giuseppe Ciaramella Human cytomegalovirus vaccine
AU2019280899A1 (en) 2018-06-08 2020-10-08 Vakzine Projekt Management Gmbh Viral particle - based vaccine
EP3587566A1 (en) 2018-06-29 2020-01-01 Bodo Plachter Hcmv vaccine strain
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733540A (en) * 1995-03-08 1998-03-31 Lee; Peter Poon-Hang Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria
DE19910044A1 (de) 1999-03-08 2000-09-14 Bodo Plachter Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
US20080044384A1 (en) * 2004-06-25 2008-02-21 Medlmmune Vaccines, Inc. Recombinant Human Cytomegalovirus And Vaccines Comprising Heterologous Antigens

Also Published As

Publication number Publication date
DK2556150T3 (en) 2016-12-05
US20130202708A1 (en) 2013-08-08
MY162335A (en) 2017-06-15
CA2795346C (en) 2022-05-03
WO2011124371A1 (en) 2011-10-13
EP2556150A1 (en) 2013-02-13
AU2011238085A1 (en) 2012-10-18
BR112012025392B1 (pt) 2021-05-25
HUE030704T2 (en) 2017-05-29
IL222229A0 (en) 2012-12-31
CN102933706A (zh) 2013-02-13
KR20130055586A (ko) 2013-05-28
JP5827312B2 (ja) 2015-12-02
PL2556150T3 (pl) 2017-05-31
AU2011238085B2 (en) 2016-08-04
RU2012146775A (ru) 2014-05-20
RU2623172C2 (ru) 2017-06-22
MX2012011639A (es) 2012-11-29
SMT201700002B (it) 2017-03-08
JP2013529065A (ja) 2013-07-18
IL222229A (en) 2017-08-31
CN102933706B (zh) 2016-01-13
SI2556150T1 (sl) 2016-12-30
RS55421B1 (sr) 2017-04-28
US9486517B2 (en) 2016-11-08
SG184261A1 (en) 2012-10-30
CA2795346A1 (en) 2011-10-13
EP2556150B1 (en) 2016-08-24
PT2556150T (pt) 2016-11-04
CY1118138T1 (el) 2017-06-28
ES2601850T3 (es) 2017-02-16
KR20170108167A (ko) 2017-09-26
KR101839535B1 (ko) 2018-04-27
HRP20161556T1 (hr) 2016-12-30
SG10201502271RA (en) 2015-05-28
BR112012025392A2 (pt) 2015-09-22

Similar Documents

Publication Publication Date Title
IL222229A0 (en) Viral particle released after infection of mammalian cells by human cytomegalovirus (hcmv) containing a fusion protein and use thereof
IL287381A (en) Pharmaceutical preparations of human rpe cells and their use
HRP20182194T1 (hr) Onkolitički herpes simpleks virus i njegova terapeutska uporaba
IL251338B (en) Plant cells and extracts containing virus-like particles containing chimeric viral proteins and compounds thereof
HK1202809A1 (en) Mammalian fetal pulmonary cells and therapeutic use of same
IL226666B (en) Methods of generating corneal cells and cell populations comprising same
IL235323A0 (en) Chimeric proteins to aid in the selection of cells infected with vaccinia virus having a specific recombinant immunoglobulin gene
EP2477650B8 (en) Virus like particles comprising target proteins fused to plant viral coat proteins
BR112013018845A2 (pt) expressão de glicoproteínas de fusão viral solúveis em células de mamífero
IL223665B (en) Human antibodies to human cytomegalovirus gb (cmv) protein
EP2616073A4 (en) INHIBITORS OF IMMERSION OF VIRUSES IN MAMMALIAN HOST CELLS
IL200187A0 (en) Recombinant antigens of human cytomegalovirus (hcmv)